医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Exome-Backed Broncus Holding Corporation Launches Hong Kong Public Offering

2021年09月25日 AM05:46
このエントリーをはてなブックマークに追加


 

NEW YORK

Exome Asset Management (“Exome”), an innovative asset management company focusing on investing in public markets across the worldwide healthcare industry, today announced it participated as a cornerstone investor in the IPO of Broncus Holding Corporation (SEHK:2216), a medical device company for the development of interventional pulmonology products headquartered in Hangzhou, China. The IPO was valued at $1.26 billion and will trade on the Stock Exchange of Hong Kong (“HKEX”). Exome was also part of Broncus Holding Corporation’s Series D round in early 2021.

Sam Isaly, Managing Partner and Chief Investment Officer of Exome Asset Management, said, “At Exome, we believe the opportunity for technological advances in pulmonology are as significant as those already achieved in cardiology. Exome is enthusiastic about our investment in Broncus, and we look forward to partnering with the company as it continues to discover and develop pulmonology products that have the potential to impact patients around the globe.”

Exome endeavors to improve the world by bringing healthcare capital to people who need it most. The firm practices two active investment strategies: one which invests broadly across worldwide healthcare subsectors and geographies, and another that is a specialized healthcare investment fund with an emphasis on public company opportunities in emerging markets. The firm is long-biased in companies that are broadly diversified by geography and healthcare subsector.

About Exome Asset Management

Exome Asset Management is an innovative asset management company focusing on investing in public markets across the worldwide healthcare industry, including pharmaceuticals, biotechnology, healthcare services, and medical devices. Exome employs sound investment strategies and a philosophy developed by Samuel D. Isaly, who has spent the majority of his 45-year career focused on both developed and emerging markets healthcare. For more information, please visit www.exomeasset.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210924005546/en/

CONTACT

Alex Forschner

Head of Business Development

(212) 403-3907

ir@exomeasset.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates